Shanghai, China, 10 December 2024 – MicroPort® MedBot™ (HKSE:2252) is proud to announce that its Toumai® Surgical Robot System has successfully completed a nerve-sparing radical prostatectomy for prostate cancer at MMT Hospital in Georgia. This marks the 100th robotic surgery at MMT Hospital, making it the first hospital in the Caucasus region to reach this achievement.
The surgery was led by Prof. Karazanashvili, a renowned urologist and President of the Georgian Urological Association, who is also the only urologist in Georgia to have received the Georgian State Prize. With the assistance of Toumai®, the complex procedure was completed in just 1 hour and 45 minutes, setting a new benchmark for surgical excellence.
Prof. Karazanashvili highlighted the transformative impact of Toumai® on minimally invasive surgery in Georgia and the Caucasus. He remarked, “The introduction of Toumai® allows us to perform surgeries with incredible precision, like having ‘miniature hands’ and ‘microscopic eyes’. Once you uses it, there’s no going back to traditional open or laparoscopic methods.” He added that the combination of expertise in open and laparoscopic techniques, along with comprehensive training and support from MicroPort® MedBot™, has been instrumental to their success.
The medical team at MMT Hospital also emphasized that many of the surgeries performed using Toumai® were highly complex procedures that were previously difficult to complete. They stated “Thanks to the Toumai® Surgical Robot, these procedures have become significantly easier, reducing postoperative recovery time and greatly improve patients' quality of life.”
Dr. He Chao, President of MicroPort® MedBot™, expressed pride in this milestone, saying “We are thrilled with the progress achieved alongside Prof. Karazanashvili’s team. Prostate cancer surgeries are now completed in just 1 hour and 45 minutes, demonstrating the efficiency and precision of the Toumai® system. We hope this success inspires more medical centers to adopt robotic surgery, benefiting even more patients.”
About MicroPort® MedBot™
Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.
More information is available at: www.medbotsurgical.com/en